Logo image of MRSN

MERSANA THERAPEUTICS INC (MRSN) Stock Fundamental Analysis

NASDAQ:MRSN - US59045L1061 - Common Stock

7.66 USD
+0.03 (+0.39%)
Last: 8/28/2025, 8:00:02 PM
7.66 USD
0 (0%)
After Hours: 8/28/2025, 8:00:02 PM
Fundamental Rating

1

MRSN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. Both the profitability and financial health of MRSN have multiple concerns. MRSN is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRSN has reported negative net income.
MRSN had a negative operating cash flow in the past year.
MRSN had negative earnings in each of the past 5 years.
MRSN had a negative operating cash flow in each of the past 5 years.
MRSN Yearly Net Income VS EBIT VS OCF VS FCFMRSN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

With a Return On Assets value of -87.54%, MRSN is not doing good in the industry: 71.85% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -87.54%
ROE N/A
ROIC N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRSN Yearly ROA, ROE, ROICMRSN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

MRSN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRSN Yearly Profit, Operating, Gross MarginsMRSN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100K -200K -300K -400K

More info and screens

1

2. Health

2.1 Basic Checks

MRSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MRSN has less shares outstanding
MRSN has more shares outstanding than it did 5 years ago.
MRSN has a worse debt/assets ratio than last year.
MRSN Yearly Shares OutstandingMRSN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
MRSN Yearly Total Debt VS Total AssetsMRSN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -17.56, we must say that MRSN is in the distress zone and has some risk of bankruptcy.
MRSN's Altman-Z score of -17.56 is on the low side compared to the rest of the industry. MRSN is outperformed by 82.08% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.56
ROIC/WACCN/A
WACC11.97%
MRSN Yearly LT Debt VS Equity VS FCFMRSN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

MRSN has a Current Ratio of 1.35. This is a normal value and indicates that MRSN is financially healthy and should not expect problems in meeting its short term obligations.
MRSN's Current ratio of 1.35 is on the low side compared to the rest of the industry. MRSN is outperformed by 81.17% of its industry peers.
A Quick Ratio of 1.35 indicates that MRSN should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.35, MRSN is not doing good in the industry: 80.62% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.35
Quick Ratio 1.35
MRSN Yearly Current Assets VS Current LiabilitesMRSN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

MRSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1477.22%.
Looking at the last year, MRSN shows a quite strong growth in Revenue. The Revenue has grown by 16.13% in the last year.
MRSN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.78% yearly.
EPS 1Y (TTM)-1477.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2335%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%33.28%

3.2 Future

MRSN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 62.02% yearly.
Based on estimates for the next years, MRSN will show a very strong growth in Revenue. The Revenue will grow by 32.52% on average per year.
EPS Next Y-324.96%
EPS Next 2Y-85.14%
EPS Next 3Y-48.49%
EPS Next 5Y62.02%
Revenue Next Year-19.09%
Revenue Next 2Y-20.28%
Revenue Next 3Y-28.78%
Revenue Next 5Y32.52%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRSN Yearly Revenue VS EstimatesMRSN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
MRSN Yearly EPS VS EstimatesMRSN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MRSN. In the last year negative earnings were reported.
Also next year MRSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRSN Price Earnings VS Forward Price EarningsMRSN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRSN Per share dataMRSN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10 -15

4.3 Compensation for Growth

A cheap valuation may be justified as MRSN's earnings are expected to decrease with -48.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-85.14%
EPS Next 3Y-48.49%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRSN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERSANA THERAPEUTICS INC

NASDAQ:MRSN (8/28/2025, 8:00:02 PM)

After market: 7.66 0 (0%)

7.66

+0.03 (+0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners70.98%
Inst Owner Change-10.24%
Ins Owners1.52%
Ins Owner Change0%
Market Cap38.22M
Analysts87.14
Price Target94.57 (1134.6%)
Short Float %N/A
Short Ratio0.19
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.78%
Min EPS beat(2)-21.54%
Max EPS beat(2)3.98%
EPS beat(4)3
Avg EPS beat(4)16.3%
Min EPS beat(4)-21.54%
Max EPS beat(4)49.71%
EPS beat(8)6
Avg EPS beat(8)11.95%
EPS beat(12)7
Avg EPS beat(12)-39.65%
EPS beat(16)8
Avg EPS beat(16)-35.45%
Revenue beat(2)0
Avg Revenue beat(2)-53.34%
Min Revenue beat(2)-53.77%
Max Revenue beat(2)-52.91%
Revenue beat(4)2
Avg Revenue beat(4)16.57%
Min Revenue beat(4)-53.77%
Max Revenue beat(4)108.93%
Revenue beat(8)3
Avg Revenue beat(8)-6.2%
Revenue beat(12)3
Avg Revenue beat(12)-18.12%
Revenue beat(16)5
Avg Revenue beat(16)-7.85%
PT rev (1m)1754.29%
PT rev (3m)1818.24%
EPS NQ rev (1m)-1501.22%
EPS NQ rev (3m)-989.29%
EPS NY rev (1m)-2127.31%
EPS NY rev (3m)-1915.63%
Revenue NQ rev (1m)91.31%
Revenue NQ rev (3m)179.92%
Revenue NY rev (1m)10.1%
Revenue NY rev (3m)-15.95%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.1
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-12.46
EYN/A
EPS(NY)-10.97
Fwd EYN/A
FCF(TTM)-15.98
FCFYN/A
OCF(TTM)-15.98
OCFYN/A
SpS6.97
BVpS-10.65
TBVpS-10.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -87.54%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-61.62%
ROA(5y)-59.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.35
Quick Ratio 1.35
Altman-Z -17.56
F-Score3
WACC11.97%
ROIC/WACCN/A
Cap/Depr(3y)129.19%
Cap/Depr(5y)101.94%
Cap/Sales(3y)4.83%
Cap/Sales(5y)339.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1477.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2335%
EPS Next Y-324.96%
EPS Next 2Y-85.14%
EPS Next 3Y-48.49%
EPS Next 5Y62.02%
Revenue 1Y (TTM)16.13%
Revenue growth 3Y904.13%
Revenue growth 5Y-0.78%
Sales Q2Q%33.28%
Revenue Next Year-19.09%
Revenue Next 2Y-20.28%
Revenue Next 3Y-28.78%
Revenue Next 5Y32.52%
EBIT growth 1Y30.2%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-45.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y11.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y8.82%
OCF growth 3YN/A
OCF growth 5YN/A